Savara Reports First Quarter Financial Results and Provides Business Update

Pivotal Phase 3 IMPALA-2 Trial Remains On-Track


Company expects trial to be fully enrolled in June 2023, on-track to report top line data by end of 2Q 2024



48-week placebo-controlled trial is... | May 15, 2023

Related Keywords

Pharma Gmb ,Matt Pauls ,Nasdaq ,Savara Inc ,Linkedin ,Twitter ,Quarter Financial Results ,Nebulizer System ,Private Securities Litigation Reform Act ,Consolidated Statements ,Savara Inc Stock Exchange ,News ,Information ,Press Release ,Pivotal ,Hase , ,Trial ,Remains ,Xpects ,O ,The ,Bully ,Unrolled ,N ,Pune ,Report ,Top ,Line ,Data ,Y ,End ,F ,Q ,Rial Svra Us8051111016 ,